| Literature DB >> 35681636 |
Qi Liu1, Wei Sun1, Hao Zhang1.
Abstract
The gut microbiota plays a crucial role in healthy individuals as well as in patients with thyroid diseases, including thyroid cancer. Although the prognosis of differentiated thyroid cancer is predictable, that of some poorly differentiated, medullary, and anaplastic thyroid cancers remains unpromising. As the interaction between the gut microbiota and thyroid cancer has been gradually revealed in recent years, the thyroid gland, a crucial endocrine organ, is shown to have a complex connection with the body's metabolism and is involved in inflammation, autoimmunity, or cancer progression. Dysbiosis of the gut microbiota and its metabolites can influence changes in hormone levels and susceptibility to thyroid cancer through multiple pathways. In this review, we focus on the interactions of the gut microbiota with thyroid function diseases and thyroid cancer. In addition, we also discuss some potential new strategies for the prevention and treatment of thyroid disease and thyroid cancer. Our aim is to provide some possible clinical applications of gut microbiota markers for early diagnosis, treatment, and postoperative management of thyroid cancer. These findings were used to establish a better multi-disciplinary treatment and prevention management strategy and to individualize the treatment of patients in relation to their gut microbiota composition and pathological characteristics.Entities:
Keywords: Graves’ disease; Hashimoto’s thyroiditis; gut microbiota; microbial metabolites; thyroid cancer
Year: 2022 PMID: 35681636 PMCID: PMC9179244 DOI: 10.3390/cancers14112656
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Gut–endocrine–thyroid cancer axis. Alterations of gut microbiota led to NIS inhibition, resulting in decreased thyroid iodine uptake and immune system, resulting in thyroid dysfunction, thyroid autoimmune diseases and thyroid cancer. Similarly, these diseases cause further changes in the gut microbiota.
Microbiota differences in thyroid diseases and thyroid cancers.
| Samples | Microbes Associated | Roles | Mechanisms | Ref. |
|---|---|---|---|---|
| TC vs. Peritumor tissue | Sphingomonas and Aeromonas ↑ in TC | Distinguish tumor and peritumor tissues | N/A | [ |
| HH vs. Healthy control | Bifidobacterium and Lactobacillus↓ in HH | N/A | N/A | [ |
| TC vs. Healthy control | Proteobacteria ↑ in TC | N/A | Decline in aminoacyl—tRNA biosynthesis, homologous recombination, mismatch repair, DNA replication, and nucleotide excision repair | [ |
| GD vs. Healthy control | Prevotellaceae and Pasteurellaceae ↑ in GD | N/A | N/A | [ |
| HT vs. Healthy control | Bacteroides ↑ and Bifidobacterium↓ in HT | Zonulin ↑ Alterations in the microbiota and intestinal permeability | N/A | [ |
| HM vs. Healthy control | Veillonella, Paraprevotella, Neisseria, and Rheinheimera↓ in HM | Positively associated with FT3 and FT4, and negatively associated with TSH | Increased serum LPS levels | [ |
| TC, TN vs. Healthy control | Neisseria ↑ and Streptococcus ↑ in TC and TN | Identify thyroid nodules and thyroid cancer | N/A | [ |
| TC vs. Healthy control | Enrichment of 19 and depletion of 8 genera in TC | Lipoprotein A ↑ and apolipoprotein B ↑ | Necroptosis | [ |
| TC vs. Peritumor tissue | Proteobacteria ↑ in TC | Closely related to TSH and T3 | Pyruvate, fatty acid metabolism and glycolysis or gluconeogenesis | [ |
| TN vs. Healthy control | Multiple butyrate producing microbes↓ | Greater amino acid degradation and lower butyrate production | L-histidine metabolism | [ |
| TC in male vs. female | Micrococcus luteus ↑ in TC | Highly correlated with immune-associated genes | DNA checkpoint and damage-related group | [ |
TC: Thyroid cancer; HH: hyperthyroid; GD: Graves’ disease; HT: Hashimoto thyroiditis; HM: hypothyroidism; TN: thyroid nodules.
Figure 2Overview of the influence of the gut microbiota on the thyroid cancers or thyroid diseases.